Pearl Meyer

ADVISOR BLOG | OCT 2023

Setting Annual Incentive Compensation Goals in Biotech



Terry Newth



Matt Molberger
MANAGING DIRECTOR

One of the most challenging compensation-related items that boards and management teams work through is the goal-setting process for the annual cash incentive plan. In most industries, companies have commercial products or services that generate financial results which can be measured and used as the basis for incentive funding purposes, are the primary value drivers for the company, and are the way its performance is gauged externally. It is quite different in the biotechnology sector where the key value drivers are often non-financial and geared toward making scientific or technical progress toward commercial products at some point in the future. This is entirely the case for precommercial companies, but holds true for larger commercial organizations as well.

Whether a therapy is viable depends on high standards around safety and efficacy, which are arguably outside of management's control. These factors suggest that management execution plays an important role in driving toward success in biotech, but ultimately the scientific results will determine whether a company is successful and able to achieve its mission.

Therein lies one of the fundamental questions in developing incentive goals in biotech: Should they be based on management execution (i.e., inputs) or the actual scientific results (i.e., outputs)?

The Basics in Biotech Incentive Design

Short-term cash incentive programs in precommercial biotechnology or life science companies tend to follow a similar structure. There are a number of key scientific, operational, financial, and organizational goals that are weighted according to their relative importance to the company in a given year. Typically, scientific goals represent a large majority of the overall weighting, followed by financial (e.g., raising funds on favorable terms) or operational depending on the company's needs, and then organizational. The methods to evaluate whether a company partially achieved, achieved, or overachieved relative to those metrics can differ by company, ranging from pure discretion to actual definitions of what constitutes achievement along the spectrum. The compensation committee and management team evaluate the results at the end of the year based on scoring each metric and applying the attributed weighting. Those individual scores are then added up to arrive at an overall corporate score.

The Challenge with Setting Goals

One of the key philosophical decisions that underlies the goal-setting process is whether the goals will be set up to be based on execution of a particular set of tasks, or the results of the topic at hand. Below is an example that illustrates the point:

Goal Theme	Execution-Based	Results-Based	
Progress Asset	Fully enroll ABC study by June	Positive data read-out from ABC	
ABC	30	study	

You could envision that the incentive funding results could be quite different based on an execution-based goal versus a results-based goal.

The Case for Execution-Based Goals

Management teams will typically prefer to have execution-based goals because they have greater influence and control over meeting the objectives and earning the associated bonus dollars. From an incentive theory perspective this is the preferred design method because the goals will drive behaviors and provide motivation. Results-based goals cannot do so to the same extent since the individual or team ultimately does not have complete control over the outcomes. The execution-based method is also beneficial from an employee retention standpoint because even if a drug or technology were to fail in achieving the desired safety, efficacy, or technological result, if the execution of that testing or process was done well then incentives could still be earned.

The Case for Results-Based Goals

Results-based goals may not have the same line of sight as execution-based goals, but they are generally more tightly linked to stakeholder goals. In this instance it would be stockholders, in the form of increased stock prices should the results of a study be positive, or patients, where positive results bring patients closer to having a therapy or medicine for their disease.

A Hybrid Model for Consideration

One possible conclusion is that there should be some hybrid design that effectively drives execution on the goals, and also rewards individuals and teams for positive clinical and technological outcomes. An approach that we believe achieves this is to create goals that provide the participants the ability to earn up to 100% of their bonus based on the execution-based outcomes of the respective goals, and only in the event that the outcomes are also positive would the participant be able to earn an above-target bonus. This balances the needs of the organization (motivation and retention), with the needs of stakeholders (incentivizing results).

Testing the Overall Rigor of the Plan

Below is an illustration of incentive funding ranges under different execution- and results-based outcomes. It could be used as a guide to back-test the draft incentive plan goals to understand if the funding outcomes are roughly in line with these rules of thumb. If the results under certain scenarios would indicate that the funding is too generous (above the range) or too punitive (below the range), the goals or weightings could be adjusted accordingly.

		Scientific/Technical Results			
		Poor	Mixed	Superior	
Execution	Superior	75 – 100%	90 – 110%	110 – 150%	
	Mixed	25 – 50%	50 – 75%	75 – 100%	
	Poor	0%	25 – 50%	50 – 75%	

It is important to note that not all goal categories, or goals themselves, lend to executionand results-based goals. Some goals may only be structured as execution-based goals, and others may only be meaningful when they are results-based.

Conclusion

Aligning pay and performance is central to most compensation philosophies and of upmost importance to investors. Goal selection is critical to building a foundation for this alignment. Compensation committees should strive to avoid paying high or relatively high bonuses based on the scorecard at a time where the stock price falls due to investor views on corporate performance. Results-based goals can build this downside protection into plans providing balance to a set of execution-based goals.

About the Authors

Terry Newth is a managing director at Pearl Meyer. He consults on the design, development, and assessment of executive compensation programs that support each organization's business objectives, long term business strategy, and organizational culture. His clients range from Fortune 500 organizations to pre-IPOs to private and family-owned companies in a wide range of industries. Terry's areas of expertise include pay strategy and philosophy development, market-based pay studies, incentive plan design, severance and CIC arrangements, outside director pay, transaction-related compensation, CD&A and supporting table disclosures, corporate governance, and share plan authorizations.

Matt Molberger is a managing director at Pearl Meyer. He consults primarily with companies in the life sciences and technology sectors. Matt works with clients to develop comprehensive executive compensation programs that support long-term business objectives. He specializes in pay benchmarking, incentive plan design, pay-for-performance alignment, security arrangements, and CD&A disclosure. Matt's client experience ranges from pre-IPO planning to supporting Fortune 500 companies throughout the annual compensation cycle.

About Pearl Meyer

Pearl Meyer is the leading advisor to boards and senior management helping organizations build, develop, and reward great leadership teams that drive long-term success. Our strategy-driven compensation and leadership consulting services act as powerful catalysts for value creation and competitive advantage by addressing the critical links between people and outcomes. Our clients stand

at the forefront of their industries and range from emerging high-growth, not-for-profit, and private							
organizations to the Fortune 500.							